Bharat Biotech to manufacture 2 Cr. Uses of covaxin at UP's Bulandshahar plant every month

13 May 2021

Bharat Biotech to manufacture 2 Cr. Uses of covaxin at UP's Bulandshahar plant every month

As state across the nation are facing acute shortage of covid-19 vaccine, the Centre Government approved the proposal of Bharat Biotech to set up a new plant Bharat immunologicals and biological Corporation Limited(BIBCOL) in UP's Bulandshahar.

As per the latest reports this new PSU will manufacture 2 Cr. doses of Covaxin every month and the central government will provide rupees 30 crore to BIBCOL for the project.

In particular, BIBCOL in Bulandshahar was established in 1989 and it manufactures oral polio vaccines and other immunisers.

There has been an acute shortage of vaccines in India as a result some States have postponed the vaccination drive for people aged between 18 to 44. The Arvind Kejriwal led national capital on Wednesday said that the people under the age of 45 won't get covaxin shots from Thursday as Limited stocks are left for the next four days.

Maharashtra too decided to temporarily suspend it's drive to vaccinate people in the age group of 18 to 44 over shortage of jabs, and divert the available stock of doses for the above 45 age group.

Meanwhile, serum Institute and Bharat Biotech submitted to the centre their Production plan for the next four months, informing they can produce it up to 10 Cr. and 7.8 Cr. doses respectively by August, official sources said on Wednesday. The Union Health ministry and the drugs controller general's office of India had sought from both the firms their Production plan for June, July, August and September months.